{'fraction_non_alphanumeric': 0.03636363636363636, 'fraction_numerical': 0.013636363636363636, 'mean_word_length': 5.172897196261682, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Secondary analysis of food group intake in prostate cancer patients undergoing radiotherapy and nutrient supplementation

Diminished nutritional intake and declining appetite are common in cancer patients during therapy. Prostate cancer patients (53) undergoing radiotherapy had 3‐day diet/activity records taken at baseline (T1), during therapy with supplementation (T3) and post‐therapy with supplementation (T4). Patients were given a Placebo, a multivitamin/mineral Dietary Reference Intake (DRI), or DRI with additional antioxidants (Orthomolecular, OM). As previously reported total sugar, carbohydrate and overall energy intake (EI) decreased significantly with Placebo, not DRI or OM. Food groups and discretionary calories (DC ‐ saturated fat, alcohol and added sugar) were examined to understand the decreased EI. Intakes of milk, vegetable, and grains did not change. DC decreased in the Placebo group during radiation. At T4 oil intake increased in the DRI group, and Placebo vs. DRI. There was a trend for an increase in meat intake at T3 in all groups and for fruit at T4 in OM. In conclusion, the decrease in EI in the Placebo group may be due to DC. Radiation therapy did not affect most food group intakes, regardless of treatment. Supported by a grant from The National Cancer Institute #R21CA102391‐2.